Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMTA Announces Strategic Partnership with Acceleron to Advance CMT Treatment Options
…developing medicines to treat serious and rare diseases, including CMT. The CMTA’s Strategy to Accelerate Research (STAR) connects top CMT clinicians and academic researchers with pharmaceutical partners committed to developing…
Seattle Focus Group with Acceleron Pharma
We are pleased to announce another opportunity to get involved with the CMTA’s Patients as Partners in Research initiative! The goal of Patients as Partners in Research is to advance…
CMTA Adds Drug Development Expert Martine Garnier to STAR Advisory Board
…disease. It does so with an aggressive, multipronged attack, bringing together a group of top-flight researchers and experts and directly funding their work. CMTA launched its Strategy to Accelerate Research,…
CMTAWinter2021Report
www.cmtausa.org WINTER 2021/2022 CMTATHE REPORT Research Grants and Collaborations Footcare for CMTers Applying for SSDI6 14 17> > > C O N TE N TS WINTER 2021/2022 RESEARCH NEW RESEARCH…
CMTA-STAR Collaboration Celebrates a Decade of CMT Genetic Discovery Through the GENESIS Database
Exciting progress from CMTA’s Strategy To Accelerate Research (STAR) program is once again highlighted with a recent publication celebrating a decade of CMT genomics discovery made possible by the GENESIS…
A Comprehensive Guide to Clinical Trials
As the CMTA’s $23.5 million investment in research begins to return dividends, more and more potential treatments are advancing to the clinical trial stage. Here’s a quick guide to clinical…
CMT Awareness Month 2023
…color print. Check out the Sky of Fame. Register for the 2023 Patient & Research Summit The 2023 CMTA Patient & Research Summit on Saturday, November 4th will offer life-improving…
CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $450K into a new scientific approach…
CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes
…the Strategy to Accelerate Research (STAR) initiative, CMTA has been at the forefront of accelerating gene replacement therapies for CMT, underscoring our leadership in this critical area of research,” said…
INC Research Study 6601
…and effective. In order to accurately measure the efficacy of a drug used to treat CMT, researchers need to know the “natural history” of the disease—how the disease would have…